Keywords: Dendreon, Provaenge, Prostate cancer, Second-quarter 2011 financial results

Dendreon scales back Provenge sales forecast; 2nd-qtr 2011 net revenue climbs to $49.6 million

Article | 05 August 2011

USA-based biotech firm Dendreon (Nasdaq: DNDN) disappointed investors when, posting second-quarter 2011 financial results, it said that it is scaling back ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Dendreon

Go to company listing

Related Drugs

Provenge

Go to drug listing